JMB-HEADER NAUKA RAS RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 52(2018) N 4 p. 570-576; DOI 10.1134/S0026893318040027 Full Text

Y.I. Ammour1*, O.O. Ryabaya2, A.V. Milovanova1, A.V. Sidorov1, I.E. Shohin4, V.V. Zverev1 , T.V. Nasedkina3

Oncolytic Properties of a Mumps Virus Vaccine Strain in Human Melanoma Cell Lines

1Mechnikov Institute of Vaccines and Sera, Moscow, 105064 Russia
2Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, 115478 Russia
3Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia
4OOO Center of Pharmaceutical Analytics, Moscow, 117246 Russia

*yulia.ammour@yahoo.fr
Received - 2017-11-20; Accepted - 2017-12-12

The oncolytic potential of the attenuated mumps virus (MV) vaccine strain Leningrad-3 (L-3) was evaluated in a panel of four human metastatic melanoma cell lines. The lines were shown to be susceptible and permissive to MV infection. Efficient MV replication led to death of melanoma cells, but the effect differed among the cell lines. Possible mechanisms mediating the selectivity of MV L-3 towards the cell lines were explored. Replicative and oncolytic activity of MV was found to depend on the expression pattern of type I interferon genes. None of the melanoma cell lines showed induction of expression of the total spectrum of genes required to inhibit virus replication. Based on the results, MV L-3 was assumed to be a promising oncolytic agent for human melanoma cells.

oncolytic viruses, mumps virus, metastatic melanoma



JMB-FOOTER RAS-JOURNALS